Related Experiment Video
Updated: Jun 18, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Hypertension epidemiology and economic burden: refining risk assessment to lower costs
1Department of Internal Medicine (Cardiology), St. Louis University School of Medicine, USA. cohenjd@swbell.net
Background:
Hypertension (HTN) continues to be a serious public health problem in the United States and is a major risk factor for stroke, heart failure, myocardial infarction, and other serious cardiovascular and renal diseases. Because HTN can be asymptomatic, its detection and control continues to be a challenge. The total economic burden of HTN is estimated at $73.4 billion in 2009.
Objective:
To examine the potential prognostic utility of biomarkers to assess hypertension-related cardiovascular risk and their potential impact on treatment in the context of current epidemiology and demographics of HTN.
Summary And Conclusions:
Although blood pressure control rates among people treated for HTN have increased from 51.3 percent to 63.9 percent over the past five years, there remains a vast unmet need for improved efficiency and effectiveness in diagnosis and treatment. Biomarkers provide a promising approach to improve detection and management of disease progression while optimizing health care expenditures.
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension and Regulation of Blood Pressure
Hypertension I: Introduction
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension II: Pathophysiology
Errors occurring during blood pressure monitoring
Several factors...